LabVantage Solutions announces new purpose-built biobanking LIMS accelerator for managing COVID-19 testing
LabVantage Solutions announced the availability of its new purpose-built COVID-19 LIMS solution. The new solution is designed to jump-start the ability of laboratories everywhere to enter biospecimens into a biobank and rapidly begin conducting COVID-19-related testing and research. The LabVantage COVID-19 Biobanking Accelerator is built on the company’s LIMS and Biobanking platforms used by clinical laboratories around the globe.
Delivered as a comprehensive Software-As-A-Service (SaaS) solution, the LabVantage COVID-19 Biobanking Accelerator requires no infrastructure investment. Being pre-configured means minimal implementation time is needed with a go-live start possible in less than four weeks. The LIMS Accelerator includes full biobanking capabilities and COVID-19 extraction and testing workflows with related master data for rapid use. It incorporates multiple protocols defined by the CDC for COVID-19 testing, and it can easily accommodate the addition of standard and customer-determined protocols for testing using a variety of approaches, such as RT-PCR, isothermal nucleic acid amplification and serology.
Leveraging LabVantage SaaS, customers pay an annual subscription fee to access the full LabVantage platform – laboratory information management system (LIMS), Biobanking solution, workflows and methods, consumables management and Seagull Scientific Bartender barcode labeling software. The package also includes start-up, training and ongoing support services, along with daily data backups and high availability support.
The LabVantage COVID-19 Biobanking Accelerator is available immediately.
